NCT05152303 is a Phase 2 clinical trial of Remimazolam Tosilate in Sedation in the ICU, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd..

Who is sponsoring NCT05152303?

NCT05152303 is sponsored by Fujian Shengdi Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05152303?

Interventions in NCT05152303: Remimazolam Tosilate, Remimazolam Tosilate.

What condition does NCT05152303 study?

NCT05152303 studies Sedation in the ICU.

Is NCT05152303 still recruiting?

NCT05152303 is currently completed. Last updated 23 May 2023.

Last reviewed 2023-05-23 · How we verify

NCT05152303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Remimazolam Tosilate for Sedation in the ICU

Completed Phase 2 Last updated 23 May 2023

What this trial tests

Phase 2 trial testing Remimazolam Tosilate in Sedation in the ICU in 60 participants. Completed in 19 April 2023.

Timeline

12 October 2022

Primary endpoint
2 April 2023

19 April 2023

Quick facts

Lead sponsor	Fujian Shengdi Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	12 October 2022
Primary completion	2 April 2023
Estimated completion	19 April 2023
Sites	1 location across China

Drugs / interventions tested

Remimazolam Tosilate — full drug profile →
Remimazolam Tosilate — full drug profile →

Conditions studied

Sedation in the ICU — all drugs for Sedation in the ICU →

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Sedation in the ICU. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the optimal dose regimen of Remimazolam Tosilate for Injection for sedation in the ICU, as well as preliminarily evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in the ICU.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Study Protocol of a Multicenter, Randomized, Single-Blind Trial: Efficacy and Safety of Remimazolam Tosylate for Sedation in ICU Patients.
Liu N, Jiang Z, Nie Y, Zuo L, et al · · 2023 · cited 2× · PMID 36920745 · DOI 10.1007/s12325-023-02456-7
Efficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study.
Liu N, Lin F, Wen J, Yu X, et al · · 2026 · PMID 42164575 · DOI 10.1016/j.jointm.2026.01.009

Verify or expand the search:

Other trials of Remimazolam Tosilate

Trials testing the same drug.

NCT07035301 — Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures · NA · completed
NCT07467603 — ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients · NA · completed
NCT06222294 — A Study of Remimazolam Tosilate for Sedation in the ICU · Phase 3 · completed
NCT06169995 — A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy · Phase 4 · completed
NCT05913336 — A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU · Phase 1, PHASE2 · completed

Other Fujian Shengdi Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06855147 — Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects · Phase 1 · completed
NCT06841445 — Efficacy and Safety of HRS9531 Tablet in Obese Subjects · Phase 2 · completed
NCT06792955 — The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution · Phase 1 · completed
NCT06723691 — Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healt · Phase 1 · completed
NCT06732154 — A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05152303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Shengdi Pharmaceutical Co., Ltd.
Last refreshed: 23 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05152303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing